|
CA2019714A1
(en)
|
1989-06-27 |
1990-12-27 |
Richard A. Chizzonite |
Process for the determination of interleukins
|
|
DZ2788A1
(fr)
|
1998-05-15 |
2003-12-01 |
Bayer Ag |
Agonistes et antagonistes selectifs à IL-2.
|
|
US6906170B1
(en)
|
1998-08-21 |
2005-06-14 |
Yeda Research And Development Co. Ltd. |
Anti-inflammatory peptides derived from IL-2 and analogues thereof
|
|
WO2001058957A2
(en)
|
2000-02-11 |
2001-08-16 |
Lexigen Pharmaceuticals Corp. |
Enhancing the circulating half-life of antibody-based fusion proteins
|
|
US6689353B1
(en)
|
2000-06-28 |
2004-02-10 |
Bayer Pharmaceuticals Corporation |
Stabilized interleukin 2
|
|
KR20030064275A
(ko)
|
2000-06-29 |
2003-07-31 |
메르크 파텐트 게엠베하 |
면역싸이토카인 흡수 증강제와의 조합 치료에 의한항체-싸이토카인 융합 단백질 매개 면역 반응 증강
|
|
CN100390282C
(zh)
|
2001-12-04 |
2008-05-28 |
默克专利有限公司 |
具有调节的选择性的il-2融合蛋白
|
|
US7569215B2
(en)
|
2003-07-18 |
2009-08-04 |
Massachusetts Institute Of Technology |
Mutant interleukin-2 (IL-2) polypeptides
|
|
US8147832B2
(en)
|
2003-08-14 |
2012-04-03 |
Merck Patent Gmbh |
CD20-binding polypeptide compositions and methods
|
|
AU2013205042B2
(en)
*
|
2004-12-22 |
2016-05-12 |
Ambrx, Inc. |
Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
|
|
KR20070102576A
(ko)
|
2005-01-27 |
2007-10-18 |
노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 |
신장 세포 암종의 치료 방법
|
|
US7667076B2
(en)
|
2005-09-14 |
2010-02-23 |
Regents Of The University Of California |
Amide forming chemical ligation
|
|
US8906356B2
(en)
|
2007-11-05 |
2014-12-09 |
Massachusetts Institute Of Technology |
Mutant interleukin-2 (IL-2) polypeptides
|
|
JP5766124B2
(ja)
|
2009-01-21 |
2015-08-19 |
アムジェン インコーポレイテッド |
炎症性疾患および自己免疫疾患の処置の組成物および方法
|
|
CU23923B1
(es)
|
2010-11-12 |
2013-07-31 |
Ct De Inmunología Molecular |
Polipéptidos derivados de la il-2 con actividad agonista
|
|
PL2637694T3
(pl)
*
|
2010-11-12 |
2021-10-18 |
Nektar Therapeutics |
Koniugaty ugrupowania IL-2 i polimeru
|
|
CA2860170C
(en)
|
2010-12-22 |
2022-06-14 |
The Board Of Trustees Of The Leland Stanford Junior University |
Superagonists and antagonists of interleukin-2
|
|
PL3489255T3
(pl)
|
2011-02-10 |
2021-11-22 |
Roche Glycart Ag |
Zmutowane polipeptydy interleukiny-2
|
|
US11492383B2
(en)
|
2011-06-24 |
2022-11-08 |
Stephen D. Gillies |
Light chain immunoglobulin fusion proteins and methods of use thereof
|
|
US9844582B2
(en)
|
2012-05-22 |
2017-12-19 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
|
|
US20160107999A1
(en)
|
2013-05-24 |
2016-04-21 |
Synaffix B.V. |
Substituted azadibenzocyclooctyne compounds and their use in metal-free click reactions
|
|
US10266502B2
(en)
|
2014-01-24 |
2019-04-23 |
Synaffix B.V. |
Process for the cycloaddition of a halogenated 1,3-dipole compound with a (hetero)cycloalkyne
|
|
EA034350B1
(ru)
|
2014-02-06 |
2020-01-30 |
Ф.Хоффманн-Ля Рош Аг |
Слитые белки, содержащие интерлейкин-2, и их применения
|
|
CA2937660A1
(en)
|
2014-02-21 |
2015-08-27 |
Nektar Therapeutics (India) Pvt. Ltd. |
Il-2rbeta-selective agonists in combination with an anti-ctla-4 antibody or an anti-pd-1 antibody
|
|
CN106659757B
(zh)
|
2014-04-24 |
2022-01-28 |
利兰斯坦福初级大学董事会 |
白介素2的超级激动剂、部分激动剂和拮抗剂
|
|
SG11201700629TA
(en)
|
2014-08-11 |
2017-02-27 |
Delinia Inc |
Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
|
WO2016025647A1
(en)
|
2014-08-12 |
2016-02-18 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
|
|
EP3180018B1
(en)
|
2014-08-12 |
2019-07-24 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with il-2 and integrin-binding-fc-fusion protein
|
|
CA2951604A1
(en)
|
2014-08-29 |
2016-03-03 |
Pablo Umana |
Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1
|
|
KR102739782B1
(ko)
|
2015-09-11 |
2024-12-09 |
더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 |
생물학적으로 관련된 직교 사이토카인/수용체 쌍
|
|
US20170204154A1
(en)
|
2016-01-20 |
2017-07-20 |
Delinia, Inc. |
Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
|
WO2017139570A1
(en)
|
2016-02-12 |
2017-08-17 |
Massachusetts Intitute Of Technology |
Synergistic tumor treatment with il-2, an integrin-binding-fc fusion protein, and a cancer vaccinne
|
|
JP6911044B2
(ja)
|
2016-03-16 |
2021-07-28 |
シェ、ヤンホイＸｉｅ Ｙａｎｈｕｉ |
呼吸器系疾患の治療のためのグルココルチコイドとポリエチレングリコール修飾インターロイキン２の組合せ
|
|
JP7422480B2
(ja)
|
2016-05-04 |
2024-01-26 |
アムジエン・インコーポレーテツド |
制御性ｔ細胞の増殖のためのインターロイキン－２変異タンパク質
|
|
US11395853B2
(en)
|
2016-06-23 |
2022-07-26 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Biomimetic drug delivery of an immunomodulatory agent for the treatment of ocular conditions
|
|
EP3475291B1
(en)
|
2016-06-28 |
2025-10-01 |
Ventana Medical Systems, Inc. |
Application of click chemistry for signal amplification in ihc and ish assays
|
|
WO2018089420A1
(en)
|
2016-11-08 |
2018-05-17 |
Delinia, Inc. |
Il-2 variants for the treatment of autoimmune diseases
|
|
MA46771A
(fr)
|
2016-11-10 |
2021-06-02 |
Univ Texas |
Méthode de traitement de tumeur immunothérapeutique
|
|
CU24483B1
(es)
|
2016-11-15 |
2020-04-02 |
Ct Inmunologia Molecular |
Método para incrementar los niveles de secreción de la interleucina-2
|
|
EP4360647A3
(en)
|
2016-12-22 |
2024-07-24 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
KR102627311B1
(ko)
*
|
2017-01-27 |
2024-01-22 |
엔지엠 바이오파마슈티컬스, 아이엔씨. |
글루카곤 수용체 결합 단백질 및 이의 사용 방법
|
|
EP3606946B1
(en)
|
2017-04-03 |
2022-08-24 |
F. Hoffmann-La Roche AG |
Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
|
|
BR112019021411A2
(pt)
|
2017-04-13 |
2020-05-05 |
Hoffmann La Roche |
métodos para tratar ou retardar a progressão do câncer e para melhorar a função, usos de um imunoconjugado, de um agonista, de um antagonista, composições, kit e invenção
|
|
CA3064435A1
(en)
|
2017-05-24 |
2018-11-29 |
Pandion Therapeutics, Inc. |
Targeted immunotolerance
|
|
WO2019112852A1
(en)
|
2017-12-06 |
2019-06-13 |
Pandion Therapeutics, Inc. |
Targeted immunotolerance
|
|
WO2018234862A1
(en)
|
2017-06-19 |
2018-12-27 |
Medicenna Therapeutics Inc. |
Uses and methods for il-2 superagonists, agonists, and fusions thereof
|
|
US20190023760A1
(en)
|
2017-07-24 |
2019-01-24 |
Eth Zurich |
Method for preparing interleukin-2 or interleukin-2 analogues
|
|
MX2020001336A
(es)
*
|
2017-08-03 |
2020-08-20 |
Synthorx Inc |
Conjugados de citoquina para el tratamiento de enfermedades autoinmunes.
|
|
EP3668548A2
(en)
|
2017-08-17 |
2020-06-24 |
Nektar Therapeutics |
Immunotherapeutic tumor treatment method
|
|
PH12020550661A1
(en)
|
2017-11-21 |
2021-04-19 |
Univ Leland Stanford Junior |
Partial agonists of interleukin-2
|
|
MA51291A
(fr)
|
2017-12-19 |
2020-10-28 |
Xencor Inc |
Protéines de fusion il-2 fc modifiées
|
|
CN111527109B
(zh)
|
2017-12-26 |
2024-11-01 |
南京金斯瑞生物科技有限公司 |
以抗体Fc区为骨架的融合蛋白二聚体及其应用
|
|
CN113166220A
(zh)
|
2018-03-09 |
2021-07-23 |
奥美药业有限公司 |
创新细胞因子前药
|
|
PE20211307A1
(es)
*
|
2018-05-21 |
2021-07-20 |
Nektar Therapeutics |
ESTIMULADOR DE TREG SELECTIVO RUR20kD-IL-2 Y COMPOSICIONES RELACIONADAS
|
|
US20210269497A1
(en)
*
|
2018-06-22 |
2021-09-02 |
Cugene Inc |
Interleukin-2 variants and methods of uses thereof
|
|
PL3849614T3
(pl)
|
2018-09-11 |
2024-04-22 |
Ambrx, Inc. |
Koniugaty polipeptydu interleukiny-2 i ich zastosowania
|
|
AU2019343251B2
(en)
|
2018-09-21 |
2022-06-09 |
Innovent Biologics (Suzhou) Co., Ltd. |
Novel interleukin 2 and use thereof
|
|
CN114949240B
(zh)
|
2019-02-06 |
2025-09-23 |
新索思股份有限公司 |
Il-2缀合物及其使用方法
|
|
KR20220009380A
(ko)
|
2019-05-17 |
2022-01-24 |
선전 엔듀어링 바이오테크 리미티드 |
표적 면역요법을 위한 절단 가능한 사이토카인이 있는 이중특이적 t-세포 연계체
|
|
EP3983001A4
(en)
|
2019-06-14 |
2023-10-04 |
Cugene Inc. |
NOVEL INTERLEUKIN-2 VARIANTS AND BIFUNCTIONAL FUSION MOLECULES THEREOF
|
|
KR20220044534A
(ko)
|
2019-08-13 |
2022-04-08 |
엘피스 바이오파마슈티컬즈 |
조작된 인터류킨-2 수용체 베타 효능제
|
|
WO2021030706A1
(en)
|
2019-08-15 |
2021-02-18 |
Synthorx, Inc. |
Immuno oncology combination therapies with il-2 conjugates
|
|
JP2022544591A
(ja)
|
2019-08-15 |
2022-10-19 |
サイティム セラピューティクス， インコーポレイテッド |
改変インターロイキン２（ｉｌ－２）ポリペプチド、コンジュゲート及びそれらの使用
|
|
PH12022500003A1
(en)
*
|
2019-09-10 |
2023-04-03 |
Synthorx Inc |
Il-2 conjugates and methods of use to treat autoimmune diseases
|
|
CN110642934B
(zh)
*
|
2019-09-10 |
2022-08-23 |
中国医学科学院北京协和医院 |
靶向调节t细胞的长效白介素-2及其在治疗自身免疫病中的应用
|
|
AU2020403148A1
(en)
|
2019-12-13 |
2022-06-30 |
Cugene Inc. |
Cytokine-based bioactivatable drugs and methods of uses thereof
|
|
MX2022013291A
(es)
|
2020-04-22 |
2023-02-14 |
Merck Sharp & Dohme Llc |
CONJUGADOS DE INTERLEUCINA 2 HUMANA SESGADOS AL DÍMERO DEL RECEPTOR DE INTERLEUCINA 2 ß?C Y CONJUGADOS CON UN POLÍMERO HIDROSOLUBLE NO PEPTÍDICO.
|
|
WO2021236474A1
(en)
|
2020-05-22 |
2021-11-25 |
Merck Sharp & Dohme Corp. |
Novel processes for preparing conjugates of the il-2 protein
|
|
WO2022140797A1
(en)
|
2020-12-23 |
2022-06-30 |
Immunowake Inc. |
Immunocytokines and uses thereof
|
|
WO2022159771A1
(en)
|
2021-01-22 |
2022-07-28 |
Elpis Biopharmaceuticals |
Anti-pd-l1 monoclonal antibodies and fusion proteins with interleukin-15 (il-15), interleukin-15 receptor 15 alpha or interleukin-2
|
|
WO2023202035A1
(zh)
*
|
2022-04-20 |
2023-10-26 |
北京大学宁波海洋药物研究院 |
受体偏向的peg化il-2变体组合及其应用
|